The Full Wiki

More info on Anidulafungin

Anidulafungin: Wikis


Note: Many of our articles have direct quotes from sources you can cite, within the Wikipedia article! This article doesn't yet, but we're working on it! See more info or our list of citable articles.

Encyclopedia

From Wikipedia, the free encyclopedia

Anidulafungin
Systematic (IUPAC) name
N-[(3S,6S,9S,11 R,15S,18S,20R,21R,24S,25 S,26S)- 6-[(1S,2R)-1,2-dihydroxy- 2-(4-hydroxyphenyl)ethyl]- 11,20,21,25-tetrahydroxy- 3,15-bis[(1R)-1-hydroxyethyl]- 26-methyl- 2,5,8,14,17,23-hexaoxo- 1,4,7,13,16,22-hexaazatricyclo [22.3.0.09,13] heptacosan-18-yl]- 4-{4-[4-(pentyloxy)phenyl]phenyl}benzamide
Identifiers
CAS number 166663-25-8
ATC code J02AX06
PubChem 166548
DrugBank APRD01301
Chemical data
Formula C 58H73N7O17  
Mol. mass 1140.24 g/mol
Pharmacokinetic data
Bioavailability  ?
Protein binding 84 %
Metabolism  ?
Half life 40-50 hours
Excretion  ?
Therapeutic considerations
Pregnancy cat.  ?
Legal status
Routes  ?

Anidulafungin or Eraxis (Ecalta in Europe) is an anti-fungal drug manufactured by Pfizer that gained approval by the Food and Drug Administration (FDA) in February 21, 2006;[1] it was previously known as LY303366. There is preliminary evidence that it has a similar safety profile to caspofungin. It has proven efficacy against oesophageal candidiasis, but its main utility will probably be in invasive Candida infection; it will probably also have application in treating invasive Aspergillus infection. It is a member of the class of anti-fungal drugs known as the echinocandins: its mechanism of action is by inhibition of (1→3)β-D-glucan synthase, which is an important component of the fungal cell wall.

Pharmacokinetics

Anidulafungin significantly differs from other antifungals in that it undergoes chemical degradation to inactive forms at body pH and temperature. Because it does not rely on enzymatic degradation or hepatic or renal excretion, the drug is safe to use in patients with any degree of hepatic or renal impairment.[2]

References

  1. ^ "FDA Approves New Treatment for Fungal Infections". FDA News Release. Food and Drug Administration. 2006-02-21. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2006/ucm108602.htm. Retrieved 2009-08-01.  
  2. ^ "Eraxis at RxList". 2009-06-24. http://www.rxlist.com/eraxis-drug.htm#cp. Retrieved 2009-08-01.  
  • Krause DS, Reinhardt J, Vazquez JA, Reboli A, Goldstein BP, Wible M, Henkel T (2004). "Phase 2, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia". Antimicrob Agents Chemother 48 (6): 2021–4. doi:10.1128/AAC.48.6.2021-2024.2004. PMID 15155194.  
  • Pfaller MA, Boyken L, Hollis RJ, Messer SA, Tendolkar S, Diekema DJ (2005). "In Vitro Activities of Anidulafungin against More than 2,500 Clinical Isolates of Candida spp., Including 315 Isolates Resistant to Fluconazole". J Clin Microbiol 43 (11): 5425–7. doi:10.1128/JCM.43.11.5425-5427.2005. PMID 16272464.  
  • Pfaller MA, Diekema DJ, Boyken L, Messer SA, Tendolkar S, Hollis RJ, Goldstein BP (2005). "Effectiveness of anidulafungin in eradicating Candida species in invasive candidiasis". Antimicrob Agents Chemother 49 (11): 4795–7. doi:10.1128/AAC.49.11.4795-4797.2005. PMID 16251335.  







Got something to say? Make a comment.
Your name
Your email address
Message